RxDoctor Payments Data

Alan Katz, MD

Internal Medicine · Melbourne, FLNPI 1861489023

Payments from drug & device makers

$3,418in general payments, 2019–2025

Across 142 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$882
  • Johnson & Johnson$846
  • Boehringer Ingelheim$409
  • Lilly USA, LLC$277
  • AstraZeneca$243
  • Cvrx, Inc.$180
  • plus $582 from 13 others

What the payments were for

  • Food & beverage$3,418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,418 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,524
Medicare patients
114
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$175,295
EliquisApixaban101$98,590
JardianceEmpagliflozin73$80,918
XareltoRivaroxaban49$61,208
Tresiba Flextouch U-100Insulin Degludec97$54,528
TrulicityDulaglutide40$52,457
BiktarvyBictegrav/Emtricit/Tenofov Ala12$45,067
MounjaroTirzepatide29$36,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$36,019
EntrestoSacubitril/Valsartan26$35,860
FarxigaDapagliflozin Propanediol25$25,261
MyrbetriqMirabegron26$22,602
JanuviaSitagliptin Phosphate14$18,297
LinzessLinaclotide18$15,572
TresibaInsulin Degludec27$13,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Tresiba$882$188,302181 claims
PfizerEliquis$30$98,590101 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$409$95,712104 claims
Lilly USA, LLCTrulicity, Mounjaro$277$88,97069 claims
Johnson & JohnsonXarelto$846$61,20849 claims
GSKTrelegy Ellipta, Breo Ellipta$96$47,40642 claims
NovartisEntresto$38$35,86026 claims
AstraZenecaFarxiga$243$25,26125 claims
AbbVieLinzess$150$15,57218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →